The Oncogene HER2/neu (ERBB2) Requires the Hypoxia-inducible Factor HIF-1 for Mammary Tumor Growth and Anoikis Resistance
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
ERBB2, a receptor tyrosine kinase amplified in breast cancer, is a well established regulator of tumor growth in vivo and anoikis resistance leading to disruption of architecture in three-dimensional mammary epithelial acinar structures in vitro . ERBB2 promotes anoikis resistance by maintaining signaling pathways and by rescuing metabolic defects and thus inhibiting accumulation of deleterious reactive oxygen species. Recent evidence suggests that hypoxia, via hypoxia-inducible factors (HIFs), can inhibit anoikis; thus, we hypothesized that HIF-1 may play a role in ERBB2-mediated anoikis resistance and oncogenesis. Indeed, tumors isolated from MMTV-Neu mice contain elevated HIF-1α levels and tumor cells created from MMTV-Neu mice harboring deletion of Hif1 α alleles reduced primary tumor growth in vivo . ERBB2 overexpressing cancer cells stabilize HIF under normoxic conditions and require HIF-1 for ERBB2-mediated anchorage-independence, three-dimensional culture growth and anoikis resistance. HIF-1 reduction in ERBB2 cells was associated with induction of the pro-anoikis protein BIM and decreased ERK and AKT signaling during cell detachment. ERBB2-mediated inhibition of metabolic defects, including decreased reactive oxygen species generation in suspension, required HIF-1 expression that was critical for ERBB2-mediated oncogenesis. Gene expression profiling of hypoxic three-dimensional acinar structures identified a number of genes elevated in response to hypoxia that are known ERBB2 targets, suggesting that hypoxic conditions and ERBB2 overexpression share both phenotypic and genetic components via HIF-1 regulation. Thus, our data demonstrate that ERBB2 requires HIF-1 for tumor growth and suggest that HIF is a major downstream regulator of ERBB2 that protects cells from anoikis and metabolic stress caused by decreased matrix adhesion. Background: Oncogene HER2 (ERBB2) regulates breast cancer growth and anoikis resistance. Results: ERBB2 requires hypoxia-inducible factor (HIF)-1 for breast cancer growth in vivo and anoikis resistance in vitro . Conclusion: HIF-1 plays a critical role in ERBB2-positive breast cancers. Significance: Genes co-regulated by ERBB2 and HIF-1 may be novel therapeutic targets for treating breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Mitochondrial Autophagy Is an HIF-1-dependent Adaptive Metabolic Response to Hypoxia
Zhang, H., Bosch-Marce, M., Shimoda, L. A., Tan, Y. S., Baek, J. H., Wesley, J. B., Gonzalez, F. J., & Semenza, G. L. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800102200 · Cited by 1,601 · cited 10×
“We identifyBNIP3L andADM as novel ERBB2-regulated genes (Fig.”
BackgroundInfluentialRetractedZhang, H., Wong, C. C. L., Wei, H., Gilkes, D. M., Korangath, P., Chaturvedi, P., Schito, L., Chen, J., Krishnamachary, B., Winnard, P. T., et al. (2012) · Oncogene · doi:10.1038/onc.2011.365 · Cited by 326
RetractedKim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905 · cited 1×
“Regulation of ROS by HIF-1 in MEFs is attributed to the direct up-regulation of PDK1 (47), which aids in inhibition of oxidative phosphorylation and BNIP3 (48), a BH3-only protein that is critical for hypoxia-driven autophagy (49).”
BackgroundHIF-1: mediator of physiological and pathophysiological responses to hypoxia
Semenza, G. L. (2000) · Journal of Applied Physiology · doi:10.1152/jappl.2000.88.4.1474 · Cited by 1,822 · cited 1×
“gen-labile HIF-1 subunit (9) that modulates the expression of a variety of genes as an integral part of the cellular response to hypoxia.”
BackgroundDefining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
Semenza, G. L. (2010) · Oncogene · doi:10.1038/onc.2009.441 · Cited by 1,712
Bellot, G., Garcia-Medina, R., Gounon, P., Chiche, J., Roux, D., Pouysségur, J., & Mazure, N. M. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00166-09 · Cited by 1,501
Laughner, E., Taghavi, P., Chiles, K., Mahon, P. C., & Semenza, G. L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.3995-4004.2001 · Cited by 1,256 · cited 3×
“Interestingly, PI3K activation is required for ERBB2-mediated metabolic rescue under conditions of low adhesion (8), which is consistent with the ability of ERBB2 via AKT to stabilize HIF-1 levels in the cancer cell (12).”
BackgroundAntioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment
Schafer, Z. T., Grassian, A. R., Song, L., Jiang, Z., Gerhart-Hines, Z., Irie, H. Y., Gao, S., Puigserver, P., & Brugge, J. S. (2009) · Nature · doi:10.1038/nature08268 · Cited by 1,031 · cited 6×
“Recent evidence suggests that oncogenes such as ERBB2 must rescue metabolic defects caused by lack of matrix attachment includingmaintaining glucose uptake that allows production of antioxidant NADPH through the pentose phosphate pathway leading to inhibition of ROS levels andmaintenance of ATP levels in suspension (8…”
BackgroundInfluentialCancer cell killing via ROS: To increase or decrease, that is the question
Wang, J., & Yi, J. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.12.7067 · Cited by 790 · cited 1×
“The induction of ROS in tumor cells also correlates with cell death through apoptosis, necrosis, and autophagy as well as reversal of chemoresistance (46).”
BackgroundBIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors
Faber, A. C., Corcoran, R. B., Ebi, H., Sequist, L. V., Waltman, B. A., Chung, E., Incio, J., Digumarthy, S. R., Pollack, S. F., Song, Y., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0106 · Cited by 283 · cited 1×
“Recent evidence showing that BIMexpression predicts responsiveness to kinase inhibitors in HER2-amplified cancers (44) suggests that increased HIF-1 expression in these tumorsmay provide protection against kinase inhibitors in normoxic and also hypoxic conditions.”
Background
Cited by
Heat Shock Proteins Promote Cancer: It's a Protection Racket
Calderwood, S. K., & Gong, J. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2016.01.003 · Cited by 407
Cancer cell survival during detachment from the ECM: multiple barriers to tumour progression
Buchheit, C. L., Weigel, K. J., & Schafer, Z. T. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3789 · Cited by 367
Mechanisms for Modulating Anoikis Resistance in Cancer and the Relevance of Metabolic Reprogramming
Adeshakin, F. O., Adeshakin, A. O., Afolabi, L. O., Yan, D., Zhang, G., & Wan, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.626577 · Cited by 271
Progress toward Overcoming Hypoxia-Induced Resistance to Solid Tumor Therapy
Reginato, M., & Karakashev, S. (2015) · Cancer Management and Research · doi:10.2147/cmar.s58285 · Cited by 95
Self-citationAnoikis evasion in inflammatory breast cancer cells is mediated by Bim-EL sequestration
Buchheit, C. L., Angarola, B. L., Steiner, A., Weigel, K. J., & Schafer, Z. T. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.209 · Cited by 63
Metadata
- Authors
- Whelan, K. A., Schwab, L. P., Karakashev, S. V., Franchetti, L., Johannes, G. J., Seagroves, T. N., & Reginato, M. J.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2013-05
- Volume
- 288
- Issue
- 22
- Pages
- 15865-15877
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2167520439
- Cited by
- 93
- References
- 10
- FWCI
- 3.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.